News Dizal breaks new ground for EGFR drugs in lung cancer Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.
News J&J's subcutaneous Rybrevant cleared by FDA J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.
News Survival data back Tagrisso's role in first-line lung cancer Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?
News J&J throws the gauntlet down to AZ with new survival data New survival data from MARIPOSA for Johnson & Johnson's Rybrevant/Lazcluze combination in lung cancer could spell trouble for AstraZeneca.
News EU approves endometrial, lung cancer drugs from GSK and J&J Both GSK and J&J have claimed pivotal approvals for growth-phase oncology therapies in the EU.
News J&J says Rybrevant combo has survival edge over Tagrisso Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.